This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

Sponsor

Tr1X, Inc. 

Status of enrollment

Accepting new patients

Ages Eligible for Study

Adults 18-65 years, will treat up to 30 years old at UCSF

Genders Eligible for Study

Female and Male

Disease indication

Adult Refractory Crohn's Disease

Principal Investigator

Sofia Verstraete MD

Contact

Paige Shave ([email protected])

Umesh Sharma ([email protected])

Additional study eligibility details can be found at UCSF Clinical Trials.